{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:04:01Z","timestamp":1777727041217,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cllc.2022.07.013","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T09:59:42Z","timestamp":1659866382000},"page":"639-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Case of Osimertinib-Induced Eosinophilic Pneumonia"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-9669","authenticated-orcid":false,"given":"Kanishka G.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarir E.","family":"Karanjawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Stollenwerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cllc.2022.07.013_bib0001","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JOP.2017.026716","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary","volume":"13","author":"Hanna","year":"2017","journal-title":"J Oncol Pract"},{"issue":"1","key":"10.1016\/j.cllc.2022.07.013_bib0002","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2022.07.013_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cllc.2022.07.013_bib0004","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2022.07.013_bib0005","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.cllc.2022.07.013_bib0006","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2004.01.010","article-title":"Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib","volume":"45","author":"Takano","year":"2004","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2022.07.013_bib0007","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2006.02.002","article-title":"Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group","volume":"52","author":"Endo","year":"2006","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.cllc.2022.07.013_bib0008","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.23490","article-title":"Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer","volume":"112","author":"Spigel","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2022.07.013_bib0009","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.lungcan.2014.09.015","article-title":"Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer","volume":"86","author":"Yoshioka","year":"2014","journal-title":"Lung Cancer"},{"issue":"27","key":"10.1016\/j.cllc.2022.07.013_bib0010","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2022.07.013_bib0011","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.07.013_bib0012","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cllc.2022.07.013_bib0013","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2022.07.013_bib0014","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.013_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10637-016-0389-9","article-title":"Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody","volume":"35","author":"Mamesaya","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cllc.2022.07.013_bib0016","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2169\/internalmedicine.8947-17","article-title":"Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease","volume":"57","author":"Kiriu","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.cllc.2022.07.013_bib0017","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jtho.2017.01.027","article-title":"Successful osimertinib rechallenge in a patient with T790M-mutant non-small cell lung cancer after osimertinib-induced interstitial lung disease","volume":"12","author":"Miyauchi","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"17","key":"10.1016\/j.cllc.2022.07.013_bib0018","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.2169\/internalmedicine.8467-16","article-title":"Interstitial lung disease induced by osimertinib for epidermal growth factor receptor (EGFR) T790M-positive Non-small cell lung cancer","volume":"56","author":"Matsumoto","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.cllc.2022.07.013_bib0019","article-title":"Emerging risk profile of lung cancer therapy: diffuse alveolar hemorrhage from osimertinib","volume":"2019","author":"Forte","year":"2019","journal-title":"Case Rep Oncol Med"},{"issue":"8","key":"10.1016\/j.cllc.2022.07.013_bib0020","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jtho.2018.04.038","article-title":"Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication","volume":"13","author":"Lee","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2022.07.013_bib0021","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/j.jtho.2017.03.022","article-title":"Osimertinib-induced interstitial lung disease presenting as eosinophilic pneumonia","volume":"12","author":"Tachi","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.013_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21037\/acr.2019.09.01","article-title":"Late-onset severe pneumonitis under osimertinib","volume":"3","author":"Syunyaeva","year":"2019","journal-title":"AME Case Rep"},{"issue":"5 Pt 1","key":"10.1016\/j.cllc.2022.07.013_bib0023","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1164\/ajrccm.150.5.7952571","article-title":"Eosinophilic lung diseases","volume":"150","author":"Allen","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.cllc.2022.07.013_bib0024","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1148\/radiology.216.3.r00se01773","article-title":"Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients","volume":"216","author":"Johkoh","year":"2000","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.cllc.2022.07.013_bib0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0033-8389(03)00109-X","article-title":"High-resolution CT of drug-induced lung disease","volume":"40","author":"Erasmus","year":"2002","journal-title":"Radiol Clin North Am"},{"issue":"2","key":"10.1016\/j.cllc.2022.07.013_bib0026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1183\/09031936.00221811","article-title":"Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia","volume":"41","author":"Rhee","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cllc.2022.07.013_bib0027","series-title":"Multislice CT. Medical Radiology","doi-asserted-by":"crossref","DOI":"10.1007\/174_2017_151","article-title":"Interstitial Lung Diseases","author":"Mueller-Mang","year":"2017"},{"issue":"4","key":"10.1016\/j.cllc.2022.07.013_bib0028","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/CMR.00025-12","article-title":"Eosinophilic pneumonias","volume":"25","author":"Akuthota","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.cllc.2022.07.013_bib0029","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jaip.2018.03.011","article-title":"Eosinophilic Pneumonias","volume":"6","author":"Allen","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.cllc.2022.07.013_bib0030","first-page":"43","article-title":"A case of sarcoidosis with eosinophilia in peripheral blood and bronchoalveolar lavage fluid","volume":"8","author":"Takahashi","year":"2013","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"10.1016\/j.cllc.2022.07.013_bib0031","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1378\/chest.126.3.993","article-title":"Eosinophilic pneumonia as an initial manifestation of rheumatoid arthritis","volume":"126","author":"Norman","year":"2004","journal-title":"Chest"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042200167X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042200167X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:12:56Z","timestamp":1761505976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042200167X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S152573042200167X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Case of Osimertinib-Induced Eosinophilic Pneumonia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}